Showing 61 - 80 results of 104,576 for search '(( a fold decrease ) OR ( 5 ((((nn decrease) OR (point decrease))) OR (a decrease)) ))', query time: 1.69s Refine Results
  1. 61
  2. 62

    sC5b-9 patients decrease in patients treated with mycophenolate mofetil. by Joshua M. Thurman (517193)

    Published 2015
    “…When analyzed separately based upon treatment, the decrease in sC5b-9 levels was due to a decrease in patients treated with mycophenolate mofetil (P < 0.001 by linear regression; n = 12 for all time-points). …”
  3. 63

    MK-STYX decreases RhoA activation. by Brittany M. Flowers (670483)

    Published 2014
    “…<p>(<b>A</b>) PC12 cells were transfected with pMT2 or pMT2-FLAG-MK-STYX-FLAG. 24 hr post-transfection cells were stimulated with 100 ng/ml NGF, and lysed at the indicated time points. …”
  4. 64
  5. 65
  6. 66
  7. 67
  8. 68
  9. 69
  10. 70
  11. 71

    A homozygous point mutation in the <i>Mrps34</i> gene causes a decrease in the MRPS34 protein. by Tara R. Richman (713532)

    Published 2015
    “…The 5′- and 3′-untranslated regions are shown as grey boxes and the predicted mitochondrial targeting sequence is shown as a black box (predicted using MitoProtII, [<a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1005089#pgen.1005089.ref040" target="_blank">40</a>]). …”
  12. 72
  13. 73
  14. 74

    Relationship between Differential Hepatic microRNA Expression and Decreased Hepatic Cytochrome P450 3A Activity in Cirrhosis by Raj Vuppalanchi (458660)

    Published 2013
    “…Six microRNAs (miR-155, miR-454, miR-582-5p, let-7f-1*, miR-181d, and miR-500) had >1.2-fold increase in cirrhotic livers and also had significant negative correlation with hepatic CYP3A activity (range of r = -0.44 to -0.52, P <0.05). …”
  15. 75

    Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5‑ASA–PABA–MAC and 5‑ASA–PABA–Diamine for the T... by Jiaxing Zhao (3965057)

    Published 2022
    “…Specifically, compound <b>20g</b> displayed a 3.67-fold decrease of plasma AUC<sub>(tofacitinib, 0–∞)</sub> and a 9.61-fold increase of colonic AUC<sub>(tofacitinib, 0–12h)</sub>, compared with tofacitinib at a molar equivalent oral dose. …”
  16. 76
  17. 77
  18. 78
  19. 79
  20. 80